MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade glioma
Acta Neuropathologica · 02.02.2025 · 149 (1)
DOI: 10.1007/s00401-025-02846-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neuropathologica, online erschienen am 02.02.2025. Verfasst von Lea L Friker und 37 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neuropathology, DGNN Brain Tumor Reference Center, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. lea.friker@ukbonn…. Hauptthemen laut MEDLINE: Mismatch Repair Endonuclease PMS2, MutS Homolog 2 Protein, MutL Protein Homolog 1, Glioma. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Niedersächsische Krebsgesellschaft e.V., Medical Faculty of the University of Bonn, Bonn, Germany, German Federal Ministry of Education and Research (BMBF).
Abstract (Originalsprache)
Pediatric high-grade glioma (pedHGG) can occur as first manifestation of cancer predisposition syndromes resulting from pathogenic germline variants in the DNA mismatch repair (MMR) genes MSH2 , MSH6 , MLH1 , and PMS2 . The aim of this study was to establish a generalized screening for Lynch syndrome and constitutional MMR deficiency (CMMRD) in pedHGG patients, as the detection of MMR deficiencies (MMRD) may enable the upfront therapeutic use of checkpoint inhibitors and identification of variant carriers in the patients’ families. We prospectively enrolled 155 centrally reviewed primary pedHGG patients for MMR-immunohistochemistry (IHC) as part of the HIT-HGG-2013 trial protocol. MMR-IHC results were subsequently compared to independently collected germline sequencing data (whole exome sequencing or pan-cancer DNA panel next-generation sequencing) available in the HIT-HGG-2013, INFORM, and MNP2.0 trials. MMR-IHC could be successfully performed in 127/155 tumor tissues. The screening identified all present cases with Lynch syndrome or CMMRD (5.5%). In addition, MMR-IHC also detected cases with exclusive somatic MMR gene alterations (2.3%), including MSH2 hypermethylation as an alternative epigenetic silencing mechanism. Most of the identified pedHGG MMRD patients had no family history of MMRD, and thus, they represented index patients in their families. Cases with regular protein expression in MMR-IHC never showed evidence for MMRD in DNA sequencing. In conclusion, MMR-IHC presents a cost-effective, relatively widely available, and fast screening method for germline MMRD in pedHGG with high sensitivity (100%) and specificity (96%). Given the relatively high prevalence of previously undetected MMRD cases among pedHGG patients, we strongly recommend incorporating MMR-IHC into routine diagnostics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Neuropathology, DGNN Brain Tumor Reference Center, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. lea.friker@ukbonn.de.
- Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany. lea.friker@ukbonn.de.
- Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.
- Styrian Children's Cancer Research, Research Unit for Cancer and Inborn Errors of the Blood and Immunity in Children, Medical University of Graz, Graz, Austria.
- Institute of Neuropathology, DGNN Brain Tumor Reference Center, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Förderung
- Niedersächsische Krebsgesellschaft e.V.
- Medical Faculty of the University of Bonn, Bonn, Germany
- German Federal Ministry of Education and Research (BMBF)
- Deutsche Kinderkrebsstiftung
- Universitätsklinikum Bonn
Zitieren
APA
Friker, L. L., Perwein, T., Waha, A., Dörner, E., Klein, R., Blattner-Johnson, M., Layer, J. P., Sturm, D., Nussbaumer, G., Kwiecien, R., Spier, I., Aretz, S., Kerl, K., Hennewig, U., Rohde, M., Karow, A., Bluemcke, I., Schmitz, A. K., Reinhard, H., …, & Kramm, C. M. (2025). MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade glioma. Acta Neuropathologica, 149(1). https://doi.org/10.1007/s00401-025-02846-x
Vancouver
Friker LL, Perwein T, Waha A, Dörner E, Klein R, Blattner-Johnson M, et al. MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade glioma. Acta Neuropathologica. 2025;149(1). doi:10.1007/s00401-025-02846-x
BibTeX
@article{Friker2025,
author = {Friker, Lea L and Perwein, Thomas and Waha, Andreas and Dörner, Evelyn and Klein, Rebecca and Blattner-Johnson, Mirjam and Layer, Julian P and Sturm, Dominik and Nussbaumer, Gunther and Kwiecien, Robert and Spier, Isabel and Aretz, Stefan and Kerl, Kornelius and Hennewig, Ulrike and Rohde, Marius and Karow, Axel and Bluemcke, Ingmar and Schmitz, Ann Kristin and Reinhard, Harald and Hernáiz Driever, Pablo and Wendt, Susanne and Weiser, Annette and Guerreiro Stücklin, Ana S and Gerber, Nicolas U and von Bueren, André O and Khurana, Claudia and Jorch, Norbert and Wiese, Maria and Kratz, Christian P and Eyrich, Matthias and Karremann, Michael and Herrlinger, Ulrich and Hölzel, Michael and Jones, David T W and Hoffmann, Marion and Pietsch, Torsten and Gielen, Gerrit H and Kramm, Christof M},
title = {MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade glioma},
journal = {Acta Neuropathologica},
year = {2025},
volume = {149},
number = {1},
doi = {10.1007/s00401-025-02846-x}
}
EUVIMED